Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Aug
28
2015
What’s in a Name? That Which We Call a Biological Product… Sheppard, Mullin, Richter & Hampton LLP
May
25
2023
Florida Bans Offshoring of Certain Patient Information Sheppard, Mullin, Richter & Hampton LLP
Jan
19
2016
Extending Patentable Life of 3D Printers: Lesson From Pharmaceutical Industry Sheppard, Mullin, Richter & Hampton LLP
Jun
22
2023
Connecticut Governor Signs Health Care Legislation to Reduce Costs and Increase Competition Sheppard, Mullin, Richter & Hampton LLP
Jan
31
2024
OIG Permits Medical Device Manufacturer’s Cost-Sharing Subsidies for Medicare Beneficiaries in Clinical Trial Sheppard, Mullin, Richter & Hampton LLP
Mar
15
2017
Foreign Investment Under Trump Administration Sheppard, Mullin, Richter & Hampton LLP
Feb
10
2021
Federal Circuit Agrees to Reconsider Ruling in GSK v. Teva Drug Patent Case Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2013
The Food and Drug Administration (FDA) Releases Long-Awaited Final Guidance on Mobile Medical Applications Sheppard, Mullin, Richter & Hampton LLP
Dec
30
2021
San Francisco Passes Measure Requiring Sick Leave for Domestic Workers – “First of Its Kind” Sheppard, Mullin, Richter & Hampton LLP
Jun
3
2014
Northern District of California Courts Still Searching for Sweet Spot in “Evaporated Cane Juice” Cases: Confusion Over Applicability of Primary Jurisdiction to ECJ Claims Continues Sheppard, Mullin, Richter & Hampton LLP
May
17
2022
California Cannabis Farmers May Finally Get Some Relief Sheppard, Mullin, Richter & Hampton LLP
Jul
26
2022
New Litigation Continues to Challenge the Social Equity and Scoring Process of the Illinois Cannabis Regulation And Tax Act Sheppard, Mullin, Richter & Hampton LLP
Nov
4
2014
Mobile Health Apps are in a Boom Phase – Why is it so Hard for Pharmaceutical Companies to Find Users? Sheppard, Mullin, Richter & Hampton LLP
Nov
28
2022
Federal Judge in NY Issues Preliminary Injunction to Block Retail Cannabis Licenses on Constitutional Grounds Sheppard, Mullin, Richter & Hampton LLP
Feb
25
2023
No Surprises Act Update: Certified IDR Entities to Resume Payment Determinations for Services Furnished Before October 25, 2022 Sheppard, Mullin, Richter & Hampton LLP
Apr
11
2023
“Dietary Guidance Statements” in Food Labeling: What You Need to Know About FDA’s Latest Draft Guidance for the Food Industry Sheppard, Mullin, Richter & Hampton LLP
Jan
22
2020
New Jersey Court Commands Cannabis Reimbursement in Workers’ Compensation Dispute Sheppard, Mullin, Richter & Hampton LLP
Jul
24
2023
Regulators Send Warning Letter to Hospitals and Telehealth Providers About Tracking Technology Use Sheppard, Mullin, Richter & Hampton LLP
Oct
18
2023
FDA’s Proposed Rule on LDT Regulation and the Debate over Agency Deference Sheppard, Mullin, Richter & Hampton LLP
Apr
7
2020
Nota Bene Episode 73: “Quarantine and Chill”: Will COVID-19 Impact the Cannabis Industry? with Whitney Hodges Sheppard, Mullin, Richter & Hampton LLP
Oct
14
2016
Proposed New FDA Labeling Rules Would Result in Increased Generic Drug Product Liability Claims Sheppard, Mullin, Richter & Hampton LLP
Jun
18
2020
President Of Medical Technology Company Charged For Promoting Fake COVID-19 Treatment Sheppard, Mullin, Richter & Hampton LLP
Apr
11
2024
China Semiconductor Export Regulations, Episode V – Updates and Corrections to the Advanced Computing and Semiconductor Regulations Sheppard, Mullin, Richter & Hampton LLP
Jan
11
2021
Medi-Cal Rx: California to Transition Medi-Cal Pharmacy Benefits to Fee-For-Service Sheppard, Mullin, Richter & Hampton LLP
Feb
18
2021
Recent FTC Settlement Serves as Reminder For Digital Health Developers Sheppard, Mullin, Richter & Hampton LLP
Jul
10
2017
Giving Telemedicine More Room to Breathe: Recent and Pending State and Federal Actions in the World of Online Prescribing Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2010
The FDA Transparency Initiative: Another One Way Street? Sheppard, Mullin, Richter & Hampton LLP
May
10
2021
Waiver Of Intellectual Property Protections For COVID-19 Vaccine Unlikely To Have Meaningful Impact In Short Term Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins